Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Personalis Inc. Common Stock (PSNL) Price & Performance

Eli Lilly And CoTrade
Personalis Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Personalis Inc. Common Stock — how do they compare? Eli Lilly And Co trades at $1,260.59 (market cap $1.08T), while Personalis Inc. Common Stock trades at $16 (market cap $1.70B). The key difference: Eli Lilly And Co is far larger — about 635.3× Personalis Inc. Common Stock's market cap, and Eli Lilly And Co pays a 0.57% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Personalis Inc. Common Stock for 0 Days on average.

LLYPSNL
Market Cap
$1.08T$1.70B
Volume
2,520,4013,262,398
Sector
HealthHealth
52-Week High
$1.28K$18.38
52-Week Low
$799.57$5.04
Typical Hold Time
94 Days0 Days
Enterprise Value
$1.12T$1.52B
Dividend Yield
0.57%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid a bullish technical outlook with strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights advancements in weight-loss and diabetes drugs, reinforcing growth prospects.

LLY's outlook remains positive, supported by a dominant position in obesity treatments and a promising pipeline. Risks include competitive pressures and high valuation multiples. Analyst consensus is strongly bullish with a $1,350 price target, though investors should monitor execution and regulatory developments.

Personalis Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LLY
20% Buy80% Sell
Avg holding period · 94 Days
PSNL
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →

About Personalis Inc. Common Stock

Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.

Read more on PSNL →